Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
EMvision Medical Devices Ltd. (EMV) vs. iShares MSCI Australia ETF (EWA)
EMvision Medical Devices Ltd. Business Overview & Revenue Model
EMvision Medical Devices Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.05M | 5.05M | 11.22M | 6.97M | 4.36M | 1.70M |
| Gross Profit | 5.05M | 5.05M | 11.22M | 6.63M | 4.12M | 1.58M |
| EBITDA | -8.71M | -8.71M | -8.35M | -5.99M | -7.84M | -9.56M |
| Net Income | -9.81M | -9.81M | -2.73M | -3.87M | -6.11M | -8.40M |
Balance Sheet | ||||||
| Total Assets | 15.57M | 15.57M | 23.97M | 11.52M | 8.51M | 10.77M |
| Cash, Cash Equivalents and Short-Term Investments | 10.53M | 10.53M | 18.67M | 9.97M | 6.80M | 9.69M |
| Total Debt | 3.53M | 3.53M | 2.90M | 3.04M | 737.86K | 213.17K |
| Total Liabilities | 6.29M | 6.29M | 5.46M | 6.40M | 1.43M | 720.01K |
| Stockholders Equity | 9.28M | 9.28M | 18.52M | 5.12M | 7.08M | 10.05M |
Cash Flow | ||||||
| Free Cash Flow | -7.89M | -7.89M | -6.29M | 646.86K | -3.97M | -4.62M |
| Operating Cash Flow | -7.84M | -7.84M | -5.99M | 834.15K | -3.78M | -4.49M |
| Investing Cash Flow | -50.37K | -50.37K | -302.41K | -187.29K | -191.12K | -127.25K |
| Financing Cash Flow | -258.34K | -258.34K | 15.00M | 2.52M | 1.08M | 8.90M |
EMvision Medical Devices Ltd. Technical Analysis
EMvision Medical Devices Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$215.65M | -130.21 | -2.01% | ― | 16.93% | 76.47% | |
48 Neutral | AU$78.91M | -57.25 | -6.35% | ― | 2.23% | -263.16% | |
47 Neutral | AU$46.89M | -2.00 | -74.00% | ― | 23.31% | -17.35% | |
46 Neutral | AU$130.03M | -9.69 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$164.50M | -15.43 | -70.55% | ― | ― | -257.32% | |
44 Neutral | AU$1.81B | -44.71 | -44.49% | ― | 55.91% | 22.60% |
EMvision Medical Devices Ltd. Corporate Events
EMvision Medical Devices has notified the ASX that 2,550,000 listed options (EMVAP), which were exercisable at $2.25 and due to expire on 31 December 2025, have lapsed without being exercised or converted, effective 31 December 2025. The expiry of these options reduces the company’s pool of potential future share issuances from this class of securities, slightly simplifying its capital structure and removing a source of possible dilution for existing shareholders.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has disclosed a change in director John Keep’s interests following the expiry and lapse of 300,000 unlisted options exercisable at $2.25 that were held through Glensburg Pty Ltd as trustee for the Tyto Corporation Pension Fund. The options expired on 31 December 2025 without being exercised, leaving Keep’s overall equity exposure unchanged in terms of ordinary shares, which remain at a combined 2,066,670 EMV shares held directly and via associated entities; the lapse removes a potential future source of share dilution and slightly reduces the director’s leveraged upside exposure to the company’s share price.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd announced the cessation of 250,000 securities due to the expiry of options without exercise or conversion as of December 1, 2025. This development may impact the company’s capital structure and could influence investor perception regarding the company’s financial strategies and future growth prospects.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has announced the issuance of 200,000 unquoted equity securities in the form of options set to expire on December 31, 2028, with an exercise price of $3.00. This issuance is part of an employee incentive scheme and is not intended to be quoted on the ASX, indicating a strategic move to retain and motivate key personnel, potentially impacting the company’s operational efficiency and market positioning.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd announced a change in the director’s interest, with Carmel Monaghan acquiring 200,000 unlisted options at an exercise price of $3.00, set to expire on December 31, 2028. This change, approved at the company’s AGM, reflects a strategic move to align the interests of the director with the company’s growth objectives, potentially impacting stakeholder confidence and market perception positively.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd successfully held its Annual General Meeting on November 11, 2025, where all proposed resolutions were passed by a poll. This outcome reflects strong shareholder support and may positively impact the company’s strategic initiatives and governance, reinforcing its position in the medical devices industry.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd announced significant progress in its mission to reduce the global burden of stroke through earlier diagnosis. The company has transitioned towards market access and commercialisation, with its emu™ device undergoing pivotal trials in major stroke centers and its First Responder device advancing to operational field evaluations. EMVision has secured substantial financial backing through grants and investments, positioning it well for upcoming clinical and regulatory milestones. The company is poised to run multiple clinical studies in the coming year, furthering its goal of making accurate stroke diagnosis more accessible globally.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has appointed Mr. Karl Pechmann as the new Chief Financial Officer, effective February 2026. Mr. Pechmann’s extensive experience in capital management and organizational development in the medical technology sector aligns with EMVision’s strategic shift from research and development to commercialization, aiming to build sustainable value for stakeholders.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has released a holdings range report for its listed options, indicating a diverse distribution of shareholders. The report highlights that a significant portion of the issued share capital is held by a small number of large stakeholders, which could impact the company’s strategic decisions and market influence.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has released a report detailing the top 20 holders of its listed options, which are set to expire in November 2027. The report highlights that Citicorp Nominees Pty Limited holds the largest share at 20.54%, followed by Keysight Technologies Inc with 9.55%. The total issued capital stands at 5,412,371, with the top 20 holders accounting for 74.13% of this capital. This distribution of holdings reflects the company’s strong institutional backing and could influence its strategic decisions and market positioning.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd announced the quotation of 5,412,371 new securities on the Australian Securities Exchange, set to expire on November 3, 2027. This move is part of previously announced transactions and reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has announced the application for quotation of 1,030,928 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction and could potentially enhance the company’s financial flexibility and market presence.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd. successfully completed an oversubscribed Share Purchase Plan (SPP), raising $2.0 million and issuing over a million new shares and options. This, combined with a recent $12.0 million placement, strengthens the company’s financial position to advance key milestones such as pivotal trial readouts, FDA submissions, and commercialization of their emu device, as well as progress in the First Responder program. The high demand led to a scale-back of applications, ensuring equitable allocation among shareholders.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has made significant progress in its Pivotal (Validation) Trial for the emu™ brain scanner, aimed at supporting regulatory submission and market entry in the US and other global markets. The company has expanded its clinical footprint in the US with the activation of UCLA Health as a trial site, and recruitment is expected to accelerate. EMVision also received a $3 million grant to evaluate an expedited stroke care model in regional hospitals, highlighting the alignment of its mission with government priorities for equitable healthcare access. Additionally, the company raised $12 million through a placement, bolstering its financial position with cash reserves of $18.35 million as of September 2025.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Limited announced that its Share Purchase Plan (SPP) has been oversubscribed, prompting the company to close the plan earlier than initially scheduled. The early closure indicates strong investor interest and support, potentially enhancing the company’s financial position and ability to advance its product development efforts.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has successfully executed a Cooperative Research Centres Projects (CRC-P) Grant Agreement with the Australian Government, receiving an initial payment of $453,566. This grant will support a collaborative project aimed at improving stroke diagnosis and management in regional emergency departments across Australia, utilizing EMVision’s emu™ point-of-care brain scanner. The study aims to demonstrate the clinical benefits of this technology, potentially leading to widespread adoption and improved patient outcomes in underserved rural areas.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.